文献速递男科与性医学

PDE5抑制剂与SERM在佩罗尼病模型中的抗纤维化协同作用

Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models.
PubMed 文献 · Eur Urol · 2018-10-19

本研究通过新型表型筛选 assay 测试21种化合物,发现PDE5抑制剂和选择性雌激素受体调节剂可显著抑制肌成纤维细胞转化。伐地那非与他莫昔芬联用在体外和体内大鼠模型中表现出协同抗纤维化效果,优于单药。

要点

  • PDE5i与SERM联用协同抑制肌成纤维细胞转化和胶原凝胶收缩。
  • 大鼠佩罗尼病模型中两药联用抗纤维化效果优于单药。
  • 提示联合治疗可能对佩罗尼病活动期有效,需临床试验验证。

核心结论

  • 首次通过表型筛选发现PDE5i与SERM在佩罗尼病模型中具有协同抗纤维化活性。

研究设计与样本

  • 开发并验证测量肌成纤维细胞转化的表型筛选assay,测试21种化合物,阳性结果进一步用体外和体内佩罗尼病模型验证。

主要发现

  • PDE5i和SERM显著抑制TGF-β1诱导的肌成纤维细胞转化。
  • 伐地那非与他莫昔芬协同抑制肌成纤维细胞转化、胶原凝胶收缩和细胞外基质产生。
  • 大鼠佩罗尼病模型中伐地那非与他莫昔芬联用的抗纤维化效果大于各单药。

关键数值与推荐

  • 表型筛选assay可检测TGF-β1诱导的肌成纤维细胞转化。
  • 伐地那非和他莫昔芬在体外协同抑制肌成纤维细胞转化、胶原凝胶收缩和细胞外基质产生。

临床怎么用

  • 基于早期体外和体内模型证据,可考虑在佩罗尼病活动期开展PDE5i与SERM联合治疗的临床试验。

局限性

  • 本研究未提供所提出协同作用的分子机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Peyronie's disease (PD) is a fibrotic disorder of the penile tunica albuginea, characterised by the formation of a localised fibrous plaque that can lead to deformity and erectile dysfunction. Nonsurgical therapeutic options for PD are limited in efficacy and safety. Myofibroblasts are key cells in the pathogenesis of PD, and inhibition of myofibroblast transformation has been suggested as a therapeutic option. OBJECTIVE: To identify potential drugs using a novel phenotypic assay and then to test them using in vitro and in vivo models of PD. DESIGN, SETTING, AND PARTICIPANTS: We have developed and validated a phenotypic screening assay that measures myofibroblast transformation, by which we tested 21 compounds that were suggested to be efficacious in treating PD. The successful hits from this assay were further tested using in vitro and in vivo models of PD. RESULTS AND LIMITATIONS: The new assay was able to detect transforming growth factor-β1-induced myofibroblast transformation. Using this assay, phosphodiesterase type 5 inhibitors (PDE5i) and selective oestrogen receptor modulators (SERMs) were identified to significantly inhibit myofibroblast transformation. A PDE5i (vardenafil) and an SERM (tamoxifen) inhibited myofibroblast transformation, collagen gel contraction, and extracellular matrix production in a synergistic fashion. In a rat model of PD, the antifibrotic effect of the combination of vardenafil and tamoxifen was greater than that of each drug alone. This study is limited by not providing a molecular mechanism for the proposed synergy. CONCLUSIONS: This is the first demonstration of a synergistic activity between a PDE5i and an SERM discovered through a phenotypic screening approach. Future clinical trials using a combination of these drugs should be considered during the active phase of PD, given the early evidence of benefit in both in vitro and in vivo models. PATIENT SUMMARY: This report suggests that the combination of a phosphodiesterase type 5 inhibitor and a selective oestrogen receptor modulator may be efficacious in treating Peyronie's disease in its active phase.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Ilg MM, Mateus M, Stebbeds WJ, et al. Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models. Eur Urol. 2018. PMID: 30344087. doi:10.1016/j.eururo.2018.10.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。